Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Assets Average (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Assets Average readings, the most recent being $20.1 million for Q1 2026.

  • On a quarterly basis, Assets Average fell 76.49% to $20.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.1 million, a 76.49% decrease, with the full-year FY2025 number at $64.7 million, down 52.9% from a year prior.
  • Assets Average hit $20.1 million in Q1 2026 for Atara Biotherapeutics, down from $25.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $432.7 million in Q1 2022 to a low of $20.1 million in Q1 2026.
  • Median Assets Average over the past 5 years was $165.4 million (2024), compared with a mean of $200.5 million.
  • Biggest five-year swings in Assets Average: dropped 21.6% in 2023 and later tumbled 79.98% in 2025.
  • Atara Biotherapeutics' Assets Average stood at $372.4 million in 2022, then tumbled by 52.43% to $177.1 million in 2023, then fell by 28.93% to $125.9 million in 2024, then tumbled by 79.98% to $25.2 million in 2025, then decreased by 20.18% to $20.1 million in 2026.
  • The last three reported values for Assets Average were $20.1 million (Q1 2026), $25.2 million (Q4 2025), and $33.5 million (Q3 2025) per Business Quant data.